Free Newsletter
Emergent gets $404M vaccine contract
It seems that hardly a week goes by in which Emergent Biosolutions doesn't get a vaccine contract. This week it's a $404 million contract with the U.S. government to provide 14.5 million doses of BioThrax anthrax vaccine. The new contract is an extension of company's current $448 million contract to supply 18.75 million doses of the vaccine. First deliveries of BioThrax under this new contract are scheduled to begin in the third quarter of 2009, when the old contract expires.
"We are encouraged that we were able to secure this new procurement for an additional 14.5 million doses with HHS, because it represents a seamless transition from our current contract for the shipment of 18.75 million doses of BioThrax into the SNS," said Fuad El-Hibri, chairman and CEO of Emergent.
- here's Emergent's release
Related Articles:
Emergent inks $29.7M anthrax vax contract
Emergent wins $24M anthrax contract
VaxGen sells anthrax vaccine to Emergent
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: